JP5396274B2 - プロオキシダント抗ガン化合物 - Google Patents

プロオキシダント抗ガン化合物 Download PDF

Info

Publication number
JP5396274B2
JP5396274B2 JP2009527656A JP2009527656A JP5396274B2 JP 5396274 B2 JP5396274 B2 JP 5396274B2 JP 2009527656 A JP2009527656 A JP 2009527656A JP 2009527656 A JP2009527656 A JP 2009527656A JP 5396274 B2 JP5396274 B2 JP 5396274B2
Authority
JP
Japan
Prior art keywords
cells
complex
tos
vitamin
prooxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009527656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010508242A5 (enExample
JP2010508242A (ja
Inventor
スティーブン・ジョン・ラルフ
イリ・ネウジル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006905109A external-priority patent/AU2006905109A0/en
Application filed by Individual filed Critical Individual
Publication of JP2010508242A publication Critical patent/JP2010508242A/ja
Publication of JP2010508242A5 publication Critical patent/JP2010508242A5/ja
Application granted granted Critical
Publication of JP5396274B2 publication Critical patent/JP5396274B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009527656A 2006-09-15 2007-09-17 プロオキシダント抗ガン化合物 Expired - Fee Related JP5396274B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006905109A AU2006905109A0 (en) 2006-09-15 Pro-oxidant Anti-cancer Compounds
AU2006905109 2006-09-15
PCT/AU2007/001371 WO2008031171A1 (en) 2006-09-15 2007-09-17 Pro-oxidant anti-cancer compounds

Publications (3)

Publication Number Publication Date
JP2010508242A JP2010508242A (ja) 2010-03-18
JP2010508242A5 JP2010508242A5 (enExample) 2013-03-28
JP5396274B2 true JP5396274B2 (ja) 2014-01-22

Family

ID=39183283

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527656A Expired - Fee Related JP5396274B2 (ja) 2006-09-15 2007-09-17 プロオキシダント抗ガン化合物

Country Status (8)

Country Link
US (1) US8410056B2 (enExample)
EP (1) EP2063884B1 (enExample)
JP (1) JP5396274B2 (enExample)
KR (1) KR101482803B1 (enExample)
AU (1) AU2007295877B2 (enExample)
CA (1) CA2663474C (enExample)
NZ (1) NZ575920A (enExample)
WO (1) WO2008031171A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598145B2 (en) 2008-03-14 2013-12-03 Stephen John Ralph Mitochondrially delivered anti-cancer compounds
US8461362B2 (en) * 2009-04-13 2013-06-11 The Ohio State University Research Foundation Protein phosphatase 2A-activating agents
KR20120100706A (ko) 2009-05-20 2012-09-12 유니베르시떼 드 제네브 암 개시세포의 미토콘드리아 활성 저해제 및 이의 용도
PT3122757T (pt) * 2014-02-28 2023-11-03 Hangzhou Dac Biotech Co Ltd Ligantes carregados e as suas utilizações em conjugação
US11007182B2 (en) 2015-04-09 2021-05-18 Health Research, Inc. Use of atpenin to activate innate immunity
KR102644587B1 (ko) * 2015-12-24 2024-03-07 (주)아모레퍼시픽 유사 세라마이드 화합물 및 그 제조방법
WO2018148550A1 (en) * 2017-02-10 2018-08-16 Health Research, Inc. Targeting mitochondrial complex ii to reduce effects of chronic hypoxia
WO2020051231A1 (en) * 2018-09-04 2020-03-12 H. Lee Moffitt Cancer Center & Research Institute Inc. Use of delta-tocotrienol for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220541A1 (en) * 1997-11-07 1999-05-07 Mcgill University Analogs of vitamin e
RU2191903C2 (ru) 1998-07-21 2002-10-27 Карпенко Анатолий Григорьевич Глушитель шума выхлопа двигателя внутреннего сгорания
CA2343893C (en) 1998-09-15 2008-12-30 Biophoretic Therapeutic Systems, Llc Iontophoretic drug delivery electrodes
EP1169033A2 (en) * 1999-04-02 2002-01-09 Washington State University Research Foundation Enhanced tissue and subcellular delivery of vitamin e compounds
JP4334472B2 (ja) * 2002-06-10 2009-09-30 学校法人北里研究所 電子伝達系の複合体ｉｉ阻害剤
US20040175415A1 (en) * 2003-03-05 2004-09-09 Chan Alvin C. Formulations and methods of delivery of intact tocopheryl succinate to humans
US6716873B1 (en) * 2003-03-20 2004-04-06 Yasoo Health Inc. Tocopherol ester compounds
RU2007107359A (ru) 2004-07-28 2008-09-10 ЭсДи ФАРМАСЬЮТИКАЛЗ, ИНК. (US) Стабильная инъецируемая композиция альфа-токоферилсукцината, его аналогов и солей
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer

Also Published As

Publication number Publication date
CA2663474C (en) 2017-06-27
EP2063884B1 (en) 2014-08-13
KR20090089845A (ko) 2009-08-24
EP2063884A1 (en) 2009-06-03
CA2663474A1 (en) 2008-03-20
US20110059898A1 (en) 2011-03-10
WO2008031171A1 (en) 2008-03-20
US8410056B2 (en) 2013-04-02
KR101482803B1 (ko) 2015-01-15
AU2007295877A1 (en) 2008-03-20
JP2010508242A (ja) 2010-03-18
AU2007295877B2 (en) 2013-04-18
NZ575920A (en) 2012-08-31
EP2063884A4 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
JP5396274B2 (ja) プロオキシダント抗ガン化合物
Fang et al. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease
Nakamura et al. Exploiting ferroptosis vulnerabilities in cancer
Boutin et al. Melatonin controversies, an update
Fulda et al. Targeting mitochondria for cancer therapy
Dong et al. α-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II
KR101642157B1 (ko) 미토콘드리아로 전달되는 항암 화합물
Ding et al. Bioevaluation of human serum albumin–hesperidin bioconjugate: insight into protein vector function and conformation
Mitani et al. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer
Zhang et al. Recent advances in the inhibition of membrane lipid peroxidation by food-borne plant polyphenols via the nrf2/gpx4 pathway
WO2008150509A1 (en) Methods and compositions for treating spinal muscular atrophy
Xie et al. In situ fluorescence imaging reveals contribution of cerebral hydroxyl radicals in hyperhomocysteinemia-induced Alzheimer-like dementia
Fernandes et al. Desrisking the cytotoxicity of a Mitochondriotropic antioxidant based on Caffeic acid by a PEGylated strategy
Ates-Alagoz Antioxidant activities of retinoidal benzimidazole or indole derivatives in In vitro model systems
Viskupicova et al. Inhibition of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA1) by rutin derivatives
Nandha et al. Anti-oxidants as therapeutic agents for oxidative stress associated pathologies: future challenges and opportunities
Sun et al. Targeting GDP-dissociation inhibitor beta (GDI2) with a benzo [a] quinolizidine library to induce paraptosis for cancer therapy
Sirvins et al. C-Nitrosation, C-Nitration, and Coupling of Flavonoids with N-Acetyltryptophan Limit This Amine N-Nitrosation in a Simulated Cured and Cooked Meat
Mossalam et al. Solid phase synthesis of mitochondrial triphenylphosphonium-vitamin E metabolite using a lysine linker for reversal of oxidative stress
AU2009225261B2 (en) Mitochondrially delivered anti-cancer compounds
Ghanim HAMLET and synthetic derivatives as pre-operative agents in the treatment of oral and oesophageal cancer
Wilson et al. Diet and Lifestyle in Prostate
Dong et al. α-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding
Chung Molecular Mechanisms of Vitamin E Secretion in Hepatocytes
Gök Investigation of the lipid metabolic changes induced by novel alpha tocopherol analog (TC6OH) in luminal A type breast cancer cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100917

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121029

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130109

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130701

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131021

R150 Certificate of patent or registration of utility model

Ref document number: 5396274

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees